Form 4: RxSight Director Tamara Fountain Sells 7,000 Shares Under 10b5-1 Trading Plan

Tamara Fountain, a director at RxSight, Inc., sold 7,000 shares of common stock on March 12, 2025, at a weighted average price of $25.7145, according to a Form 4 filing with the SEC.

Summary

• On March 12, 2025, Tamara Fountain, a director of RxSight, Inc. (RXST), sold 7,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $25.7145 per share.
• The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on December 11, 2024.
• Following the reported transaction, Fountain directly owns 24,793 shares of RxSight common stock.
• The filing also includes an exhibit for Power of Attorney, granting authority to several individuals to act on Fountain's behalf regarding SEC filings.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a stock sale by a company director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning. The establishment of a 10b5-1 trading plan allows insiders to sell shares over a period of time without being accused of trading on non-public information.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates concerns about insider trading.

Key Dates